Aytu Biopharma (AYTU) Liabilities from Discontinued Operations (2024)
Aytu Biopharma's (AYTU) quarterly Liabilities from Discontinued Operations came in at $557000.0 in Q2 2024.
Powered by 
Analysis
Aytu Biopharma (AYTU) Liabilities from Discontinued Operations (2024) Analysis & Trends
Aytu Biopharma (AYTU) has reported Liabilities from Discontinued Operations for 1 consecutive years, with $557000.0 the latest figure, recorded in Q2 2024.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to $557000.0 in Q2 2024; TTM through Jun 2024 was $557000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $557000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was $557000.0 for Q2 2024 at Aytu Biopharma.
- Over five years, Liabilities from Discontinued Operations peaked at $557000.0 in Q2 2024 and troughed at $557000.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn |